key: cord-0829688-lvvw1npq
authors: Ioannidis, John P A
title: Infection fatality rate of COVID-19 inferred from seroprevalence data
date: 2021-01-01
journal: Bull World Health Organ
DOI: 10.2471/blt.20.265892
sha: 9954fa14d44ea6ce54f1084cff91afcc3d2ee0c4
doc_id: 829688
cord_uid: lvvw1npq

OBJECTIVE: To estimate the infection fatality rate of coronavirus disease 2019 (COVID-19) from seroprevalence data. METHODS: I searched PubMed and preprint servers for COVID-19 seroprevalence studies with a sample size ≥ 500 as of 9 September 2020. I also retrieved additional results of national studies from preliminary press releases and reports. I assessed the studies for design features and seroprevalence estimates. I estimated the infection fatality rate for each study by dividing the cumulative number of COVID-19 deaths by the number of people estimated to be infected in each region. I corrected for the number of immunoglobin (Ig) types tested (IgG, IgM, IgA). FINDINGS: I included 61 studies (74 estimates) and eight preliminary national estimates. Seroprevalence estimates ranged from 0.02% to 53.40%. Infection fatality rates ranged from 0.00% to 1.63%, corrected values from 0.00% to 1.54%. Across 51 locations, the median COVID-19 infection fatality rate was 0.27% (corrected 0.23%): the rate was 0.09% in locations with COVID-19 population mortality rates less than the global average (< 118 deaths/million), 0.20% in locations with 118–500 COVID-19 deaths/million people and 0.57% in locations with > 500 COVID-19 deaths/million people. In people younger than 70 years, infection fatality rates ranged from 0.00% to 0.31% with crude and corrected medians of 0.05%. CONCLUSION: The infection fatality rate of COVID-19 can vary substantially across different locations and this may reflect differences in population age structure and case-mix of infected and deceased patients and other factors. The inferred infection fatality rates tended to be much lower than estimates made earlier in the pandemic.

The infection fatality rate, the probability of dying for a person who is infected, is one of the most important features of the coronavirus disease 2019 (COVID- 19) pandemic. The expected total mortality burden of COVID-19 is directly related to the infection fatality rate. Moreover, justification for various non-pharmacological public health interventions depends on the infection fatality rate. Some stringent interventions that potentially also result in more noticeable collateral harms 1 may be considered appropriate, if the infection fatality rate is high. Conversely, the same measures may fall short of acceptable risk-benefit thresholds, if the infection fatality rate is low.

Early data from China suggested a 3.4% case fatality rate 2 and that asymptomatic infections were uncommon, 3 thus the case fatality rate and infection fatality rate would be about the same. Mathematical models have suggested that 40-81% of the world population could be infected, 4, 5 and have lowered the infection fatality rate to 1.0% or 0.9%. 5, 6 Since March 2020, many studies have estimated the spread of the virus causing COVID-19 -severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) -in various locations by evaluating seroprevalence. I used the prevalence data from these studies to infer estimates of the COVID-19 infection fatality rate.

The input data for calculations of infection fatality rate were studies on the seroprevalence of COVID-19 done in the general population, or in samples that might approximately represent the general population (e.g. with proper reweighting), that had been published in peer-reviewed journals or as preprints (irrespective of language) as of 9 September 2020. I considered only studies with at least 500 assessed samples because smaller data sets would result in large uncertainty for any calculations based on these data. I included studies that made seroprevalence assessments at different time intervals if at least one time interval assessment had a sample size of at least 500 participants. If there were different eligible time intervals, I selected the one with the highest seroprevalence, since seroprevalence may decrease over time as antibody titres decrease. I excluded studies with data collected for more than a month that could not be broken into at least one eligible time interval less than one month duration because it would not be possible to estimate a point seroprevalence reliably. Studies were eligible regardless of the exact age range of participants included, but I excluded studies with only children.

I also examined results from national studies from preliminary press releases and reports whenever a country had no other data presented in published papers or preprints. This inclusion allowed these countries to be represented, but information was less complete than information in published papers or preprints and thus requires caution.

I included studies on blood donors, although they may underestimate seroprevalence and overestimate infection fatality rate because of the healthy volunteer effect. I excluded studies on health-care workers, since this group is at a potentially high exposure risk, which may result in seroprevalence estimates much higher than the general population and thus an improbably low infection fatality rate. Similarly, I also excluded studies on communities (e.g. shelters or religious or other shared-living communities). Studies were eligible regardless of whether they aimed to evaluate seroprevalence in large or small regions, provided that the population of reference in the region was at least 5000 people.

I searched PubMed® (LitCOVID), and medRxiv, bioRxiv and Research Square using the terms "seroprevalence" OR "antibodies" with continuous updates. I made the first search in early May and did monthly updates, with the last update Objective To estimate the infection fatality rate of coronavirus disease 2019 (COVID-19) from seroprevalence data. Methods I searched PubMed and preprint servers for COVID-19 seroprevalence studies with a sample size ≥ 500 as of 9 September 2020. I also retrieved additional results of national studies from preliminary press releases and reports. I assessed the studies for design features and seroprevalence estimates. I estimated the infection fatality rate for each study by dividing the cumulative number of COVID-19 deaths by the number of people estimated to be infected in each region. I corrected for the number of immunoglobin (Ig) types tested (IgG, IgM, IgA). Findings I included 61 studies (74 estimates) and eight preliminary national estimates. Seroprevalence estimates ranged from 0.02% to 53.40%. Infection fatality rates ranged from 0.00% to 1.63%, corrected values from 0.00% to 1.54%. Across 51 locations, the median COVID-19 infection fatality rate was 0.27% (corrected 0.23%): the rate was 0.09% in locations with COVID-19 population mortality rates less than the global average (< 118 deaths/million), 0.20% in locations with 118-500 COVID-19 deaths/million people and 0.57% in locations with > 500 COVID-19 deaths/million people. In people younger than 70 years, infection fatality rates ranged from 0.00% to 0.31% with crude and corrected medians of 0.05%. Conclusion The infection fatality rate of COVID-19 can vary substantially across different locations and this may reflect differences in population age structure and case-mix of infected and deceased patients and other factors. The inferred infection fatality rates tended to be much lower than estimates made earlier in the pandemic. 

John P A Ioannidis a Research Infection fatality rate of COVID- 19 John P A Ioannidis on 9 September 2020. I contacted field experts to retrieve any important studies that may have been missed. From each study, I extracted information on location, recruitment and sampling strategy, dates of sample collection, sample size, types of antibody measured (immunoglobulin G (IgG), IgM and IgA), the estimated crude seroprevalence (positive samples divided by all samples tested), adjusted seroprevalence and the factors that the authors considered for adjustment.

If a study did not cover an entire country, I collected information on the population of the relevant location from the paper or recent census data so as to approximate as much as possible the relevant catchment area (e.g. region(s) or county(ies)). Some studies targeted specific age groups (e.g. excluding elderly people and/or excluding children) and some estimated numbers of people infected in the population based on specific age groups. For consistency, I used the entire population (all ages) and, separately, the population 0-70 years to estimate numbers of infected people. I assumed that the seroprevalence would be similar in different age groups, but I also recorded any significant differences in seroprevalence across age strata so as to examine the validity of this assumption.

I calculated the number of infected people by multiplying the relevant population size and the adjusted estimate of seroprevalence. If a study did not give an adjusted seroprevalence estimate, I used the unadjusted seroprevalence instead. When seroprevalence estimates with different adjustments were available, I selected the analysis with largest adjustment. The factors adjusted for included COVID-19 test performance, sampling design, and other factors such as age, sex, clustering effects or socioeconomic factors. I did not adjust for specificity in test performance when positive antibody results were already validated by a different method.

For the number of COVID-19 deaths, I chose the number of deaths accumulated until the date 1 week after the midpoint of the study period (or the date closest to this that had available data) -unless the authors of the study had strong arguments to choose some other time point or approach. The 1-week lag accounts for different delays in developing antibodies versus dying from infection. The number of deaths is an approximation because it is not known when exactly each patient who died was infected. The 1-week cut-off after the study midpoint may underestimate deaths in places where patients are in hospital for a long time before death, and may overestimate deaths in places where patients die soon because of poor or even inappropriate care. Whether or not the health system became overloaded may also affect the number of deaths. Moreover, because of imperfect diagnostic documentation, COVID-19 deaths may have been both overcounted and undercounted in different locations and at different time points.

I calculated the inferred infection fatality rate by dividing the number of deaths by the number of infected people for the entire population, and separately for people younger than 70 years. I took the proportion of COVID-19 deaths that occurred in people younger than 70 years from situational reports for the respective locations that I retrieved at the time I identified the seroprevalence studies. I also calculated a corrected infection fatality rate to try and account for the fact that only one or two types of antibodies (among IgG, IgM, IgA) might have been used. I corrected seroprevalence upwards (and inferred infection fatality rate downwards) by one tenth of its value if a study did not measure IgM and similarly if IgA was not measured. This correction is reasonable based on some early evidence, 7 although there is uncertainty about the exact correction factor.

The estimates of the infection fatality rate across all locations showed great heterogeneity with I 2 exceeding 99.9%; thus, a meta-analysis would be inappropriate to report across all locations. Quantitative synthesis with metaanalysis across all locations would also be misleading since locations with high COVID-19 seroprevalence would tend to carry more weight than locations with low seroprevalence. Furthermore, locations with more studies (typically those that have attracted more attention because of high death tolls and thus high infection fatality rates) would be represented multiple times in the calculations. In addition, poorly conducted studies with fewer adjustments would get more weight because of spu-riously narrower confidence intervals than more rigorous studies with more careful adjustments which allow for more uncertainty. Finally, with a highly skewed distribution of the infection fatality rate and with large between-study heterogeneity, typical random effects models would produce an incorrectly high summary infection fatality rate that approximates the mean of the study-specific estimates (also strongly influenced by high-mortality locations where more studies have been done); for such a skewed distribution, the median is more appropriate.

Therefore, in a first step, I grouped estimates of the infection fatality rate from studies in the same country (or for the United States of America, the same state) together and calculated a single infection fatality rate for that location, weighting the study-specific infection fatality rates by the sample size of each study. This approach avoided inappropriately giving more weight to studies with higher seroprevalence estimates and those with seemingly narrower confidence intervals because of poor or no adjustments, while still giving more weight to larger studies. Then, I used the single summary estimate for each location to calculate the median of the distribution of location-specific infection fatality rate estimates. Finally, I explored whether the location-specific infection fatality rates were associated with the COVID-19 mortality rate in the population (COVID-19 deaths per million people) in each location as of 12 September 2020; this analysis allowed me to assess whether estimates of the infection fatality rate tended to be higher in locations with a higher burden of death from COVID-19.

I retrieved 61 studies with 74 eligible estimates published either in the peerreviewed literature or as preprints as of 9 September 2020. Furthermore, I considered another eight preliminary national estimates. [69] [70] [71] [72] [73] [74] [75] [76] This search yielded a total of 82 eligible estimates (Fig. 1) .

The studies varied substantially in sampling and recruitment designs (Table 1 ; available at: http:// www .who .int/ bulletin/ volumes/ 99/ 1/ 20 -265892). Of the 61 studies, 24 studies 8, 10, 16, 17, 20, 22, 25, 33, 34, 36, 37, 42, [46] [47] [48] [49] [52] [53] [54] 57, 61, 63, 65, 68 Infection fatality rate of COVID-19 John P A Ioannidis explicitly aimed for random sampling from the general population. In principle, random sampling is a stronger design. However, even then, people who cannot be reached (e.g. by email or telephone or even by visiting them at a house location) will not be recruited, and these vulnerable populations are likely to be missed. Moreover, several such studies 8, 10, 16, 37, 42 focused on geographical locations with high numbers of deaths, higher than other locations in the same city or country, and this emphasis would tend to select eventually for a higher infection fatality rate on average.

Eleven studies assessed blood donors, 12, 15, 18, 24, 28, 31, 41, 44, 45, 55, 60 which might underestimate COVID-19 seroprevalence in the general population. For example, 200 blood donors in Oise, France showed 3.00% seroprevalence, while the seroprevalence was 25.87% (171/661) in pupils, siblings, parents, teachers and staff at a high school with a cluster of cases in the same area; the true population seroprevalence may be between these two values. 13 For other studies, healthy volunteer bias 19 may underestimate seroprevalence, attracting people with symptoms 26 may overestimate seroprevalence, and studies of employees, 14, 21, 25, 32, 66 grocer y store clients 23 or patient cohorts 11, 14, [27] [28] [29] [30] 36, 38, 40, 50, 51, 56, 59, 62, 64, 67 risk sampling bias in an unpredictable direction.

All the studies tested for IgG antibodies but only about half also assessed IgM and few assessed IgA. Only seven studies assessed all three types of antibodies and/or used pan-Ig antibodies. The ratio of people sampled versus the total population of the region was more than 1:1000 in 20 studies ( 

Seroprevalence for the infection ranged from 0.02% to 53.40% (58.40% in the slum sub-population in Mumbai; Table 3 ). Studies varied considerably depending on whether or not they tried to adjust their estimates for test performance, sampling (to get closer to a more representative sample), clustering (e.g. when including household members) and other factors. The adjusted seroprevalence occasionally differed substantially from the unadjusted value. In studies that used samples from multiple locations, between-location heterogeneity was seen (e.g. 0.00-25.00% across 133 Brazilian cities). 25

Inferred infection fatality rate estimates varied from 0.00% to 1.63% (Table 4) . Corrected values also varied considerably (0.00-1.54%).

For 15 locations, more than one estimate of the infection fatality rate was available and thus I could compare the infection fatality rate from different studies evaluating the same location. The estimates of infection fatality rate tended to be more homogeneous within each location, while they differed markedly across locations (Fig. 2) . Within the same location, infection fatality rate estimates tend to have only small differences, even though it is possible that different areas within the same location may also have real differences in infection fatality rate. France is one exception where differences are large, but both estimates come from population studies of outbreaks from schools and thus may not provide good estimates of population seroprevalence and may lead to an underestimated infection fatality rate. I used summary estimates weighted for sample size to generate a single estimate for each location. Data were available for 51 different locations (including the inferred infection fatality rates from the eight preliminary additional national estimates in Table 5 ).

The median infection fatality rate across all 51 locations was 0.27% (corrected 0.23%). Most data came from locations with high death tolls from COVID-19 and 32 of the locations had a population mortality rate (COVID-19 deaths per million population) higher than the global average (118 deaths from COVID-19 per million as of 12 September 2020; 79 Fig. 3 ). Uncorrected estimates of the infection fatality rate of COVID-19 ranged from 0.01% to 0.67% (median 0.10%) across the 19 locations with a population mortality rate for COVID-19 lower than the global average, from 0.07% to 0.73% (median 0.20%) across 17 locations with population mortality rate higher than the global average but lower than 500 COVID-19 deaths per million, and from 0.20% to 1.63% (median 0.71%) across 15 locations with more than 500 COVID-19 deaths per million. The corrected estimates of the median infection fatality rate were 14 10 ND NA 1 108 000 China (Wuhan) 32 8 39 10.4 ND NA 620 105 France (Oise) 13 25.9 ND NA 1 548 000 Germany (Gangelt) 16 67 3.8 3.6 Age, sex 54 000 Islamic Republic of Iran (Guilan) 8 22 33 .0 Test, sampling 770 000 Italy (Apulia), blood donors 31 0.99 ND NA 39 887 Japan (Kobe) 11 3.3 2.7 Age, sex 40 999 Japan (Tokyo) 29 3.83 ND NA 532 450 Japan (Utsunomiya City) 48 0 64 3 ND NA 512 910 Pakistan (Karachi) 49 16 . 30 14.3 ND NA 1 081 938 Switzerland (Geneva) 10 10 65 5.6 6.0 Test, sampling 3 360 000 United Kingdom (Scotland) blood donors 18 1.2 ND NA 64 800 USA (10 states) 35 Washington, Puget Sound USA (California, Santa Clara) 19 1.5 2.6 Test, sampling, cluster 51 000 USA (Idaho, Boise) 9 1.79 ND NA 8620 USA (Georgia, DeKalb and Fulton counties) 53 2.7 2.5 Age, sex, race and ethnicity 45 167 USA (Idaho, Blaine County) 46 22 . b An estimate is also provided adjusting for test performance, but the assumed specificity of 99.0% seems inappropriately low, since as part of the validation process the authors found that several of the test-positive individuals had household members who were also infected, thus the estimated specificity was deemed by the authors to be at least 99.95%. c 1.20% in workers in Split without mobility restrictions, 3.37% in workers in Knin without mobility restrictions, 1.57% for all workers without mobility restrictions; Split and Knin tended to have somewhat higher death rates than nationwide Croatia, but residence of workers is not given, so the entire population of the country is used in the calculations. d An estimate is also provided adjusting for test performance resulting in adjusted seroprevalence of 0.23%, but this seems inappropriately low, since the authors report that all positive results were further validated by ELISA (enzyme-linked immunosorbent assay). e 5.0% with point of care test, 4.6% with immunoassay, 3.7% with both tests positive, 6.2% with at least one test positive. f Patients during 1-15 April. g Blood donors in May. h The study counts in prevalence also those who were currently/recently infected as determined by a positive RT-PCR. Notes: Of the studies where seroprevalence was evaluated at multiple consecutive time points, the seroprevalence estimate was the highest in the most recent time interval with few exceptions, for example: in the Switzerland (Geneva) study, 10 the highest value was seen 2 weeks before the last time interval; in the Switzerland (Zurich) study, 28 the highest value was seen in the period 1-15 April for patients at the university hospital and in May for blood donors; and in the China (Wuhan) study, 32 16 7 (15 April) 0.28 (0.25) 0 0.00 (0.00) Germany (Frankfurt) 21 42 e (17 April 11 10 (mid-April) 0.02 (0.02) 21 (Japan) 0.01 (0.01) Japan (Tokyo) 29 189 (11 May) 0.04 (0.03) 21 (Japan) 0.01 (0.01) Japan (Utsunomiya City) 48 0 (14 June) 0.00 (0.00) 0 0.00 (0.00) Kenya, blood donors 44 64 ( 24 12 (22 March a Whenever the number or proportion of COVID-19 deaths at age < 70 years was not provided in the paper, I retrieved the proportion of these deaths from situation reports of the relevant location. If I could not find this information for the specific location, I used a larger geographic area. For Brazil, the closest information that I found was from a news report. 77 For Croatia, I retrieved data on age for 45/103 deaths through Wikipedia. 78 Geographical location in parentheses specifies the population b Data are provided by the authors for deaths per 100 000 population in each city along with inferred infection fatality rate in each city, with wide differences across cities; the infection fatality rate shown here is the median across the 36 cities with 200-250 samples and at least one positive sample (the interquartile range for the uncorrected infection fatality rate is 0.20-0.60% and across all cities is 0-2.4%, but with very wide uncertainty in each city). A higher infection fatality rate is alluded to in the preprint, but the preprint also shows a scatter diagram for survey-based seroprevalence versus reported deaths per population with a regression slope that agrees with an infection fatality rate of 0.3%. c Information on deaths was not available for the specific locations. In the Sao Paulo study, the authors selected six districts of Sao Paulo most affected by COVID-19; they do not name the districts and the number of deaths as of mid-May is not available, but using data for death rates across all Sao Paulo would give an infection fatality rate of > 0.4% overall. In the Vitacura study, similarly one can infer from the wider Santiago metropolitan area that the infection fatality rate in the Vitacura area would probably be < 0.2% overall. d For France, government situation reports provide the number of deaths per region only for in-hospital deaths; therefore, I multiplied the number of in-hospital deaths by a factor equal to: total number of deaths/in-hospital deaths for all of France. e Estimated from number of deaths in Hesse province on 17 April × proportion of deaths in the nine districts with key enrolment (enrolment ratio > 1:10 000) in the study among all deaths in Hesse province. f I calculated the approximate number of deaths assuming the same case fatality ratio in the Srinagar district as in the Jammu and Kashmir state where it is located. g For Karachi, it is assumed that about 30% of COVID-19 deaths in Pakistan are in Karachi (since about 30% of the cases are there). h The number of deaths across all Pakistan; I assumed that this number is a good approximation of deaths in urban areas (most deaths occur in urban areas and there is some potential underreporting). i I calculated the approximate number of deaths from the number of cases in the study areas in south-western Seoul, assuming a similar case fatality as in Seoul overall. j Confirmed COVID-19 deaths; inclusion of probable COVID-19 deaths would increase the infection fatality rate estimates by about a quarter. Note: Cumulative deaths are sourced from the specific study or from situation report on the same location unless otherwise stated. 0.09%, 0.20% and 0.57%, respectively, for the three location groups.

For people younger than 70 years old, the infection fatality rate of CO-VID-19 across 40 locations with available data ranged from 0.00% to 0.31% (median 0.05%); the corrected values were similar.

The infection fatality rate is not a fixed physical constant and it can vary substantially across locations, depending on the population structure, the case-mix of infected and deceased individuals and other, local factors. The studies analysed here represent 82 different estimates of the infection fatality rate of COVID-19, but they are not fully representative of all countries and locations around the world. Most of the studies are from locations with overall COVID-19 mortality rates that are higher than the global average. The inferred median infection fatality rate in locations with a COVID-19 mortality rate lower than the global average is low (0.09%). If one could sample equally from all locations globally, the median infection fatality rate might even be substantially lower than the 0.23% observed in my analysis.

COVID-19 has a very steep age gradient for risk of death. 80 Moreover, in European countries that have had large numbers of cases and deaths 81 , and in the USA 82 , many, and in some cases most, deaths occurred in nursing homes. Locations with many nursing home deaths may have high estimates of the infection fatality rate, but the infection fatality rate would still be low among non-elderly, non-debilitated people.

Within China, the much higher infection fatality rate estimates in Wuhan compared with other areas of the country may reflect widespread nosocomial infections, 83 as well as unfamiliarity with how to manage the infection as the first location that had to deal with COVID-19. The very many deaths in nursing homes, nosocomial infections and overwhelmed hospitals may also explain the high number of fatalities in specific locations in Italy 84 and New York and neighbouring states. 23, 27, 35, 56 Poor decisions (e.g. sending COVID-19 patients to nursing homes), poor management (e.g. unnecessary mechanical ventilation and hydroxychloroquine) may also have contributed to worse outcomes.

High levels of congestion (e.g. in busy public transport systems) may also have exposed many people to high infectious loads and, thus, perhaps more severe disease. A more aggressive viral clade has also been speculated. 85 The infection fatality rate may be very high among disadvantaged populations and in settings with a combination of factors predisposing to higher fatalities. 37 Ve r y l ow i n f e c t i on f at a l it y rates seem common in Asian coun- tries. 8, 11, 29, 48, 49, 51, 59, 61, 67 A younger population in these countries (excluding Japan), previous immunity from exposure to other coronaviruses, genetic differences, hygiene etiquette, lower infectious load and other unknown factors may explain these low rates. The infection fatality rate is low also in low-income countries in both Asia and Africa, 44,49,66,67 perhaps reflecting the young age structure. However, comorbidities, poverty, frailty (e.g. malnutrition) and congested urban living circumstances may have an adverse effect on risk and thus increase infection fatality rate.

Antibody titres may decline with time 10, 28, 32, 86, 87 and this would give falsely low prevalence estimates. I considered the maximum seroprevalence estimate when multiple repeated measurements at different time points were available, but even then some of this decline cannot be fully accounted for. With four exceptions, 10,28,32,51 the maximum seroprevalence value was at the latest time point.

Positive controls for the antibody assays used were typically symptomatic patients with positive polymerase chain reaction tests. Symptomatic patients may be more likely to develop antibodies. [87] [88] [89] [90] [91] Since seroprevalence studies specifically try to reveal undiagnosed asymptomatic and mildly symptomatic infections, a lower sensitivity for these mild infections could lead to substantial underestimates of the number of The survey was done in Tbilisi, the capital city with a population 1.1 million. I could not retrieve the count of deaths in Tbilisi, but if more deaths happened in Tbilisi, then the infection fatality rate may be higher, but still < 0.1%. c Assuming a seroprevalence of 2.5%. Notes: These are countries for which no eligible studies were retrieved in the literature search. The results of these studies have been announced to the press and/or in preliminary reports, but are not yet peer reviewed and published.

Corrected infection fatality rate (%) 

Infection fatality rate of COVID-19 John P A Ioannidis infected people and overestimates of the inferred infection fatality rate. A main issue with seroprevalence studies is whether they offer a representative picture of the population in the assessed region. A generic problem is that vulnerable people at high risk of infection and/or death may be more difficult to recruit in survey-type studies. COVID-19 infection is particularly widespread and/or lethal in nursing homes, in homeless people, in prisons and in disadvantaged minorities. 92 Most of these populations are very difficult, or even impossible, to reach and sample and they are probably under-represented to various degrees (or even entirely missed) in surveys. This sampling obstacle would result in underestimating the seroprevalence and overestimating infection fatality rate.

In principle, adjusted seroprevalence values may be closer to the true estimate, but the adjustments show that each study alone may have unavoidable uncertainty and fluctuation, depending on the type of analysis chosen. Furthermore, my corrected infection fatality rate estimates try to account for undercounting of infected people when not all three antibodies (IgG, IgM and IgA) were assessed. However, the magnitude of the correction is uncertain and may vary in different circumstances. An unknown proportion of people may have responded to the virus using immune mechanisms (mucosal, innate, cellular) without generating any detectable serum antibodies. [93] [94] [95] [96] [97] A limitation of this analysis is that several studies included have not yet been fully peer-reviewed and some are still ongoing. Moreover, despite efforts made by seroprevalence studies to generate estimates applicable to the general population, representativeness is difficult to ensure, even for the most rigorous studies and despite adjustments made. Estimating a single infection fatality rate value for a whole country or state can be misleading, when there is often huge variation in the population mixing patterns and pockets of high or low mortality. Furthermore, many studies have evaluated people within restricted age ranges, and the age groups that are not included may differ in seroprevalence. Statistically significant, modest differences in seroprevalence across some age groups have been observed in several studies. 10, 13, 15, 23, 27, 36, 38 Lower values have been seen in young children and higher values in adolescents and young adults, but these patterns are inconsistent and not strong enough to suggest that major differences are incurred by extrapolating across age groups.

Acknowledging these limitations, based on the currently available data, one may project that over half a billion people have been infected as of 12 September 2020, far more than the approximately 29 million documented laboratory-confirmed cases. Most locations probably have an infection fatality rate less than 0.20% and with appropriate, precise non-pharmacological measures that selectively try to protect high-risk vulnerable populations and settings, the infection fatality rate may be brought even lower. ■ Funding: METRICS has been supported by a grant from the Laura and John Arnold Foundation.

Competing interests: I am a co-author (not principal investigator) of one of the seroprevalence studies. 

Objectif Estimer le ratio de létalité réel de la maladie à coronavirus 2019 (COVID-19) à partir des données de séroprévalence. Méthodes J'ai effectué des recherches sur PubMed et sur les serveurs de prépublication afin de trouver des études consacrées à la séroprévalence de la COVID-19, avec des échantillons ≥ 500, au 9 septembre 2020. J'ai également prélevé des résultats supplémentaires dérivés d'études nationales qui figurent dans les versions préliminaires de divers rapports et communiqués de presse. J'ai analysé les études pour y déceler des caractéristiques de conception et des estimations de séroprévalence. Ensuite, j'ai calculé le ratio de létalité réel pour chaque étude en divisant le nombre cumulé de décès dus à la COVID-19 par le nombre d'individus qui auraient été infectés dans chaque région. Enfin, j'ai apporté des corrections en fonction des types d'anticorps testés (immunoglobulines, IgG, IgM, IgA). Résultats J'ai pris 61 études en compte (74 estimations) et huit estimations nationales préliminaires. Les estimations en matière de séroprévalence étaient comprises entre 0,02% et 53,40%. Les ratios de létalité réels allaient de 0,00% à 1,63%, les valeurs corrigées de 0,00% à 1,54%. Dans les 51 lieux étudiés, la médiane du ratio de létalité réel pour la COVID-19 s'élevait à 0,27% (0,23% après correction): le ratio était de 0,09% dans les endroits où le taux de mortalité dû à la COVID-19 était inférieur à la moyenne mondiale (< 118 décès/million d'habitants), de 0,20% dans les endroits dénombrant 118-500 décès COVID-19/ million d'habitants, et de 0,57% là où la COVID-19 était responsable de > 500 décès/million d'habitants. Chez les personnes de moins de 70 ans, les ratios de létalité réels se situaient entre 0,00% et 0,31% avec des médianes brutes et corrigées de 0,05%. Conclusion Le ratio de létalité réel de la COVID-19 peut considérablement varier d'un endroit à l'autre, ce qui pourrait correspondre aux différences de structure de pyramide des âges au sein de la population, au casemix entre patients infectés et décédés, ainsi qu'à d'autres facteurs. Les ratios de létalité réels que j'ai pu déduire avaient tendance à être nettement inférieurs aux estimations formulées précédemment durant la pandémie.

Цель Оценить показатель летальности при инфицировании коронавирусным заболеванием 2019 г. (COVID-19) на основании данных о серораспространенности. Методы Автор провел поиск на серверах PubMed и серверах предварительной публикации на предмет исследований серораспространенности COVID-19 с размером выборки ≥500 по состоянию на 9 сентября 2020 года. Были также получены дополнительные результаты национальных исследований из предварительных пресс-релизов и отчетов. Автор оценил исследования по элементам дизайна и оценкам серораспространенности. Автор оценил показатель летальности при инфицировании для каждого исследования, разделив общее количество смертей от COVID-19 на количество людей, предположительно инфицированных в каждом регионе. При этом была сделана поправка на количество протестированных типов антител (иммуноглобины, IgG, IgM, IgA).

Результаты В работу вошло 61 исследование (74 прогноза) и восемь предварительных национальных прогнозов. Прогнозы серораспространенности варьировались в диапазоне от 0,02 до 53,40%. Показатели летальности при инфицировании варьировались в диапазоне от 0,00 до 1,63%, скорректированные значения -от 0,00 до 1,54%. В 51 регионе средний показатель летальности при инфицировании COVID-19 составил 0,27% (скорректированный показатель 0,23%): этот показатель составил 0,09% в регионах с уровнем летальности населения от COVID-19 ниже, чем в среднем по миру (<118 смертей на миллион), 0,20% в регионах, в которых зарегистрировано 118-500 случаев смерти от COVID-19 на миллион человек, и 0,57% в регионах, где зарегистрировано более 500 случаев смерти от COVID-19 на миллион человек. У людей младше 70 лет показатель летальности при инфицировании колебался в пределах от 0,00 до

Infection fatality rate of COVID-19 John P A Ioannidis 0,31% с приблизительными и скорректированными медианными значениями 0,05%. Вывод Показатель летальности при инфицировании COVID-19 может существенно различаться в разных регионах, и это может отражать различия в возрастной структуре населения, структуре случаев инфицирования и смерти пациентов, а также в других факторах. Предполагаемые показатели летальности при инфицировании, как правило, были намного ниже, чем прогнозы, сделанные ранее во время пандемии.

Tasa de letalidad por la infección de la COVID-19 calculada a partir de los datos de seroprevalencia

Objetivo Estimar la tasa de letalidad por la infección de la enfermedad por coronavirus de 2019 (COVID-19) a partir de los datos de seroprevalencia.

Métodos Se buscaron los estudios de seroprevalencia de la COVID-19 con un tamaño de muestra mayor o igual a 500 a partir del 9 de septiembre de 2020 en PubMed y en los servidores de preimpresión. Además, se recuperaron los resultados adicionales de los estudios nacionales a partir de los comunicados de prensa y de los informes preliminares. Se evaluaron los estudios para determinar las características de diseño y las estimaciones de seroprevalencia. Para calcular la tasa de letalidad por la infección de cada estudio, se dividió la cantidad acumulada de muertes por la COVID-19 por la cantidad de personas que se estima que están infectadas en cada región. Asimismo, se corrigió la cantidad de tipos de anticuerpos probados (inmunoglobulinas, IgG, IgM, IgA).

Resultados Se incluyeron 61 estudios (74 estimaciones) y 8 estimaciones nacionales preliminares. Las estimaciones de seroprevalencia oscilaban entre el 0,02 % y el 53,40 %. Las tasas de letalidad por la infección oscilaron entre el 0,00 % y el 1,63 %, los valores corregidos entre el 0,00 % y el 1,54 %. En 51 lugares, la mediana de la tasa de letalidad por la infección de la COVID-19 fue del 0,27 % (corregida en un 0,23 %): la tasa fue del 0,09 % en lugares donde las tasas de letalidad de la población con la COVID-19 eran inferiores al promedio mundial (menos de 118 muertes/millón), del 0,20 % en lugares con 118-500 muertes a causa de la COVID-19/millón de personas y del 0,57 % en lugares con más de 500 muertes a causa de la COVID-19/millón de personas. En personas menores de 70 años, las tasas de letalidad por la infección oscilaron entre el 0,00 % y el 0,31 % con medianas brutas y corregidas del 0,05 %. Conclusión La tasa de letalidad por infección de la COVID-19 puede variar de manera sustancial en diferentes lugares y esto puede reflejar diferencias en la estructura de edad de la población y en la variedad de casos de los pacientes infectados y fallecidos, así como en otros factores. Las tasas de letalidad por infección que se calculan tienden a ser mucho más bajas que las estimaciones realizadas a principios de la pandemia. 60 China (Guangzhou) 23 March-2 April Healthy blood donors in Guangzhou Xu et al. 40 China (several  regions) 30 March-10 April Voluntary participation by public call for haemodialysis patients (n = 979 in Jingzhou, Hubei and n = 563 in Guangzhou/Foshan, Guangdong) and outpatients in Chongqing (n = 993), and community residents in Chengdu, Sichuan (n = 9442), and required testing for factory workers in Guangzhou, Guandong (n = 442) Jerkovic et al. 26 Croatia 23-28 April DIV Group factory workers in Split and Sibenik-Knin invited for voluntary testing Erikstrup et al. 12 Denmark 6 April-3 May All Danish blood donors aged 17-69 years giving blood. Blood donors are healthy and must comply with strict eligibility criteria; they must self-defer for two weeks if they develop fever with upper respiratory symptoms Petersen et al. 52 Denmark (Faroe  Islands) 27 April-1 May 1 500 randomly selected residents invited to participate, samples collected from 1075 Fontanet et al. 39 France (Crepy-en-Valois)

Pupils, their parents and relatives, and staff of primary schools exposed to SARS-CoV-2 in February and March 2020 in a city north of Paris Fontanet et al. 13 France (Oise) 30 March-4 April Pupils, their parents and siblings, as well as teachers and nonteaching staff of a high-school Streeck et al. 16 Germany ( Cross-sectional household surveys in a low-(district Malir) and high-transmission (district East) area of Karachi with households selected using simple random sampling (Malir) and systematic random sampling (East) Javed et al. 66 Pakistan (urban Karachi, Lahore, Multan, Peshawar and Quetta)

Up to 6 July Adult, working population aged 18-65 years, recruited from dense, urban workplaces including factories, businesses, restaurants, media houses, schools, banks, hospitals (health-care providers), and from families of positive cases in cities in Pakistan Abu Raddad et al. 51 Qatar 12 May-12 July (highest seroprevalence on 12-31 May)

Convenience sample of residual blood specimens collected for routine clinical screening or clinical management from 32 970 outpatient and inpatient departments for a variety of health conditions (n = 937 in 12-31 May) Noh et al. 59 Republic of Korea 25-29 May Outpatients who visited two hospitals in south-west Seoul which serve six administrative areas Pollán et al. 36 Spain a Sample collection time for some sub-cohorts may have exceeded 1 month, but more than half of the cases were already documented by polymerase chain reaction testing before any antibody testing and the last death occurred on 20 April. Note: Some studies included additional data sets that did not fulfil the eligibility criteria (e.g. had sample size < 500 or were health-care workers) and they are not presented here.

Should governments continue lockdown to slow the spread of covid-19?

Geneva: World Health Organization

Geneva: World Health Organization

How many people might one person with coronavirus infect?

Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand

A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates

Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital

Seroprevalence of COVID-19 virus infection in Guilan province

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe

Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors

Cluster of COVID-19 in northern France: a retrospective closed cohort study

Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan

Herd immunity is not a realistic exit strategy during a COVID-19 outbreak

Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event

Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil

Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors -a pilot study of the value of serology to determine population exposure

COVID-19 Antibody Seroprevalence

Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study

Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area

Seroprevalence of SARS-CoV-2-specific antibodies among adults in

Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York

SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area

Remarkable variability in SARS-CoV-2 antibodies across Brazilian regions: nationwide serological household survey in 27 states

SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Sibenik-Knin County

SARS-CoV-2 IgG antibody responses in New York City

Early plateau of SARS-CoV-2 seroprevalence identified by tripartite immunoassay in a large population

Geographical profiles of COVID-19 outbreak in Tokyo: an analysis of the primary care clinic-based point-of-care antibody testing. J Prim Care Community Health

Seroprevalence and clinical spectrum of SARS-CoV-2 infection in the first versus third trimester of pregnancy

Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2

Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan

Cold Spring Harbor: medRxiv

SARS-CoV-2 community transmission during shelter-in-place in San Francisco

A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage

Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States

ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Seroprevalence of SARS-CoV-2 and infection fatality ratio

Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium -a prospective cross sectional study of residual samples

SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission

Cold Spring Harbor: medRxiv

Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

Grupo Hemorio de Pesquisa em Covid-19. Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro

SARS-CoV-2 seroprevalence in the municipality of São Paulo, Brazil, ten weeks after the first reported case

SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors

Low seroprevalence of SARS-CoV-2 in Rhode Island blood donors determined using multiple serological assay formats

High community SARS-CoV-2 antibody seroprevalence in a ski resort community

Cold Spring Harbor: medRxiv

Community-level SARS-CoV-2 seroprevalence survey in urban slum dwellers of

Cold Spring Harbor: medRxiv

Seroprevalence of SARS-CoV-2 IgG antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household-and population-based study

Serial population based serosurvey of antibodies to SARS-CoV-2 in a low and high transmission area of Karachi

Low SARS-CoV-2 sero-prevalence based on anonymized residual serosurvey before and after first wave measures in British Columbia

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic

Seroprevalence of SARS-CoV-2-specific antibodies

Emerg Infect Dis

CDC Field Surveyor Team. Estimated community seroprevalence of SARS-CoV-2 antibodies -two Georgia counties

Population point prevalence of SARS-CoV-2 infection based on a statewide random sample -Indiana

The prevalence of antibodies to SARS-CoV-2 among blood donors in China

Antibody testing documents the silent spread of SARS-CoV-2 in New York prior to the first reported case

HUNgarian COronaVirus-19 Epidemiological Research (H-UNCOVER) investigators. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. Geroscience

Humoral immune response to SARS-CoV-2 in Iceland

Seroprevalence of anti-SARS-CoV-2 antibodies among outpatients in southwestern Seoul

Low prevalence of antibodies against SARS-CoV-2 among voluntary blood donors in Guangzhou

Seroprevalence of SARS-CoV-2 in slums and non-slums of Mumbai

Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies

Racial and workplace disparities in seroprevalence of SARS-CoV-2 in

Homologous and he 1 terologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands

Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults

Sero-prevalence findings from metropoles in Pakistan: implications for assessing COVID-19 prevalence and case-fatality within a dense, urban working population

Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India -a cross-sectional study

Population-based seroprevalence of SARS-CoV-2 is more than halfway through the herd immunity threshold in the State of Maranhão, Brazil

Weekly report of the population serology survey of the corona epidemic

Solna: Swedish Public Health Agency

Prague: Institute of Health Information and Statistics of the Czech Republic

Coronavirus herd immunity? Not in Israel, according to a serological study. Jerusalem Post

Ljubljana: Republic of Slovenia

Ten million Afghans likely infected and recovered: COVID-19 survey. VOA

Preliminary results of seroprevalence study in Tbilisi: 10 out of 1068 residents have coronavirus antibodies. Agenda.ge

In Brazil, COVID-19 hitting young people harder. The Jakarta Post

COVID-19 pandemic in Croatia [internet]. Wikipedia; 2020

COVID-19 coronavirus pandemic

Population-level COVID-19 mortality risk for non-elderly individuals overall and for nonelderly individuals without underlying diseases in pandemic epicenters

Half of coronavirus deaths happen in care homes, data from EU suggests. The Guardian

American Geriatrics Society Policy Brief: COVID-19 and nursing homes

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

What other countries can learn from Italy during the COVID-19 pandemic

Distinct viral clades of SARS-CoV-2: implications for modeling of viral spread

Serological signatures of SARS-CoV-2 infection: implications for antibodybased diagnostics

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection

Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay

Antibody profiling of COVID-19 patients in an urban low-incidence region in northern Germany

Global perspective of COVID-19 epidemiology for a full-cycle pandemic

Innate immune evasion by human respiratory RNA viruses

The human antibody response to influenza A virus infection and vaccination

Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19

Intrafamilial exposure to SARS-CoV-2 induces cellular immune response without seroconversion

Karolinska COVID-19 Study Group. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

 38 3 391 (20-26 April) IgG 11 589 623 86 Brazil (133 cities) 25 24 995 IgG and IgM 74 656 499 94 (Brazil) Brazil (Espirito Santo) 34 4 608 IgG and IgM 4 018 650 94 (Brazil) Brazil (Maranhao) 68 3 156 IgG and IgM 7 114 598 92 Brazil (Rio de Janeiro), blood donors 41 669 ( 12 20 640 IgG and IgM 5 771 876 86 Denmark (Faroe Islands) 52 1 075 IgG and IgM 52 428 88 France (Crepy-en-Valois) 39 1 21 1 000 IgG 2 681 000 e 84 (Germany) Greece 62 6 586 (4 511 in April) IgG 10 412 967 84 Hungary 57 10 504 IgG (also had RT-PCR) 11 1 000 IgG 1 518 870 79 (Japan) Japan (Tokyo) 29 1 071 IgG 13 902 077 79 (Japan) Japan (Utsunomiya City) 48 742 IgG 518 610 79 (Japan) Kenya, blood donors 44 3 098 IgG 47 564 296 99 Luxembourg 20 1 807IgG and IgA f 615 729 90 Netherlands blood donors 15 49 1 004 IgG and IgM 16 700 000 98 (Pakistan) Pakistan (urban) 66 24 24 1 000 IgG 7 753 000 90 USA (California, Los Angeles) 22 863 IgG and IgM 7 892 000 92 USA (California, San Francisco) 33 3 1 020 000) . In this table and subsequent analyses, the entire population in the location is considered for consistency across studies. c Information in parentheses specifies the population. d When the population of the relevant location was not given in a specific study, information on recent estimates of the pertinent population was obtained by standard online sources such as: populationpyramid.net, worldpopulationreview.com, worldometers .info/ coronavirus, and Wikipedia. e Participants were recruited from a large number of districts, but most districts had very few participants; here I included the population of the nine districts with > 1:10 000 sampling ratio (846/1000 participants came from these nine districts). f Considered positive if both IgG and IgA were positive; in the other studies, detection of any antibody was considered positive.